Myelodysplastic syndromes

Hematology and Cell Therapy

Volumn 38, Issue 5, 1996, Pages 363-380

  Fenaux, P ^a  

^a Service de Pathologie Professionnelle et Environnement   (France)

Author keywords

allogeneic bone marrow; cytogenetics; myelodysplastic syndromes; P53 gene; RAS gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ALPHA INTERFERON; ANDROGEN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DANAZOL; DEFEROXAMINE; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MERCAPTOPURINE; PROTEIN P53; TENIPOSIDE; VITAMIN D DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; CYTOGENETICS; HUMAN; INCIDENCE; MYELODYSPLASTIC SYNDROME; ONCOGENE RAS; REVIEW;

EID: 0029852833     PISSN: 14302772     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-996-0363-7     Document Type: Review

References (110)

1. Aul C, Gattermann N, Schneider W (1995) Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymph 16 : 247-262
2. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87 : 743-745
3. Passmore SJ, Hanni M, Stillier CA et al (1995) Pediatric myelodysplasia : a study of 68 children and a new prognostic scoring system. Blood 85 : 1742-50
4. Fenaux P, Lucidarme J, Lai JL, Bauters F (1989) "Favorable" cytogenetic abnormalities in secondary leukemia.Cancer 63 : 2505-2508
5. Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 19 : 47-84
6. Pedersen-Bjefgaard J, Philip P, Larsen SO, et al (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76 : 1083-91
7. Pedersen-Bjergaard J, Philip P (1991) Two different classes of therapy-related and de novo acute myeloid leukemia ? Cancer Genet Cytogenet 55 : 119-124
8. Stone RM (1994) Myelodysplastic syndrome after autologous transplantation for lymphoma : the price of progress ? Blood 83 : 3437-3440
9. Aksoy M (1985) Malignancies due to occupational exposure to benzene. Am J Med 2 : 217-245
10. Farrow A, Jacobs A, West RR (1989) Myelodysplasia, chemical exposure, and other environmental factors. Leukemia 3 : 33-35
11. Nisse C, Lorthois C, Dorp V, et al (1995) Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia 9 : 693-699
12. Luna-Fineman S, Shannon KM, Lange BJ (1995) Childhood monosomy 7 : epidemiology, biology, and mechanistic implications. Blood 85 : 1985-1989
13. Bader-Meunier B, Mielot F, Tchernia G, et al (1996) Myelodysplastic syndromes in childhood : report of 49 patients from a French multicenter study. Br J Haematol 92 : 344-350
14. Socie G, Henry-Amar M, Bacigalupo A (1993) Transplant Registry-Severe Aplastic Anemia Working Party Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 329-1152
15. Morel P, Hebbar M, Lai JL, et al (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system : a report on 408 cases. Leukemia 7 : 1315-23
16. Fenaux P, Morel P, Lai JL (1996) Cytogenetics of myelodysplastic syndromes. Sem Hematol 33 : 127-138
17. Nowell PC (1992) Chromosome abnormalities in myelodysplastic syndromes. Sem Oncol 19 : 25-33
18. Pierre RV, Catovsky D, Mufti GJ et al (1989) Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40 : 149-161
19. Flactif M, Lai JL, Preudhomme C, et al (1994) Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. Leukemia 8 : 1012-1018
20. Jenkins RB, Le Beau MM, Kraker WJ et al (1992) Fluorescence in situ hybridization : a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 79 : 3307-15
21. Bos JL (1989) Ras oncogenes in human cancer. A review. Cancer Res 49 : 4682-4689
22. Horiike S, Misawa S, Nakai H. et al (1994) N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8 : 1331-1336
23. Paquette RL, Landaw EM, Pierre V, et al (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82 : 590-599
24. Shannon KM, O'Connell P, Martin GA et al (1994) Loss of the normal NFl allele from the bone marrow in children with type 1 neurofibromatoses and malignant myeloid disorders. N Engl J Med 330 : 587-601
25. Largaespada DA, Brannan CI, Jenkins NA, et al (1996) NF1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genet 12 : 137
26. Preudhomme C, Vachee A, Quesnel B et al (1993) Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodyspiastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia 7 : 1071
27. Ridge SA, Worwood M, Oscier M, et al (1990) FMS mutations in myelodysplastic, leukemic and normal subjects. Proc Natl Acad Sci USA 87 : 1377-1380
28. Jonveaux Ph, Fenaux P, Pignon JM (1991) Mutation in the p53 gene in myelodysplastic syndromes. Oncogene 6 : 2243-47
29. Lai JL, Preudhomme C, Zandecki M, et al (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9 : 370-381
30. Preudhomme C, Vachee A, Lepelley P, et al (1994) Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br J Haematol 87 : 61-67
31. Golub TR, Bvarker GF, Lovett M, et al (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 : 307
32. Wessels JW, Fibbe WE, Van Der Keur D et al (1993) t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet 65-7
33. Nucifora G, Rowley JD (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86 : 1-14
34. Van Den Berghe H, Vermaelen K, Mecucci C (1985) The 5q-anomaly. Cancer Genet Cytogenet 17 : 189-255
35. Boultwood J, Lewis S, Wainscoat JS (1994) The 5q- syndrome. Blood 84 : 3253-60
36. Fairman J, Chumakov I, Chinault A et al (1995) Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci USA 92 : 7406-7410
37. Le Beau MM, Espinosa R, Neuman W, et al (1993) Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 90 : 5485-8
38. Pedersen B, Jensen IM (1991) Clinical and prognostic implications of chromosome 5q deletions : 96 high resolution studied patients. Leukemia 5 : 556-573
39. Roulston D, Espinosa R, Stoffel M, et al (1993) Molecular genetics of myeloid leukemia : identification of the commonly deleted segment of chromosome 20. Blood 82 : 3424-3429
40. Pereira Velloso ER, Michaux L, Ferrant A, et al (1996) Deletions of the long arm of chromosome 7 in myeloid disorders : loss of band 7q32 implies worst prognosis. Br J Haematol 92 : 574-581
41. Van Kamp H, Fibbe WE, Jansen RPM, et al (1990) Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia : analysis by X-linked restriction fragment polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene.Blood 80 : 1774-1780
42. Anan K, Ito M, Misawa M, et al (1995) Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene. Br J Haematol 89 : 838-844
43. Preudhomme C, Vachee A, Morschauser F, et al (1994) Immunoglobulin and T cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. Leukemia 18 : 365-371
44. Soenen V, Fenaux P, Flactif M, et al (1995) Combined immunophenotyping and in situ hybridization (Fiction) : a rapid method to study cell lineage involvement in myelodysplastic syndromes. Brit J Haematol 90 : 701-706
45. Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Sem Hematol 33 : 150-162
46. Mufti GJ, Figes A, Hamblin TJ, et al (1986) Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Hematol 63 : 143-147
47. Hebbar M, Brouillard M, Wattel E, et al (1995) Association of myelodysplastic syndrome and relapsing polychondritis : further evidence. Leukemia ç : 731-733
48. Michet CJ, McKenna CH, Luthra HS, et al (1986) Relapsing polychondritis : survival and predictive role of early disease manifestations. Ann Intern Med 104 : 74-78
49. Wattel E, Cambier N, Caulier MT, et al (1994) Androgen therapy in myelodysplastic syndromes with thrombocytopenia : a report on 20 cases. Br J Haematol 87 : 205-208
50. Hebbar M, Kaplan C, Caulier MT, et al (1996) Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy Br J Haematol (in press)
51. Cazzola M, Barosi G, Berzuini C, et al (1982) Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes.Br J Haematol 50 : 55-62
52. Coutinho LH, Geary CG, Chang J, et al (1990) Functional studies of bone marrow haematopoietic and stromal cells in the myelodysastic syndromes (MDS). Br J Haematol 75 : 16-25
53. Zwierzina H, Schollenberger S, Herold M, et al (1992) Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res 16 : 1181-1186
54. Hellstrom-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes : a meta-analysis of 205 patients from 17 studies. Br J Haematol 89, 67-71
55. Hirayama Y, Kohgo Y, Matsunaga T, et al (1993) Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 1993, 85 : 676-683
56. Mareni C., Sessarego M., Montera M., Fugazza G., Origone P., D'amato E., Lerza R., Pistola V., Bianchi Scarra G. Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes. Leuk. Lymph., 1994, 15 : 135-141
57. Raza A., Gezer S., Mundle S, Gao X.Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 1995, 86 : 268-276
58. Kouides P.A., Bennett J.M. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Sem. Hematol., 1996, 33 : 95-110
59. Tricot G., De Wolf-Peeters C, Hendrickx B. Et Al. Bone marrow histology in myelodysplastic syndromes : I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br. J. Haematol., 1984, 57 : 423-430
60. Tricot G., De Wolf-Peeters C., Vlietinck R. Et Al. Bone marrow histology in myelodysplasic syndromes. II. Pronogstic value of abnormal localization of immature precursors in MDS. Br.J.Haematol., 1984, 58 : 217-225
61. Takagi S., Tanaka O., Miura Y. Magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes or leukemia. Blood, 1995, 86 : 316-322
62. Greenberg P.L. Biological and clinical implications of marrow culture studies in the myelodysplastic syndromes. Sem. Hematol., 1996, 33 : 163-175
63. Fenaux P., Beuscart R., Lai J.L. Et Al. Prognostic factors in adult chronic myelomonocytic leukemia : An analysis of 107 cases. J. Clin. Oncol., 1988, 6 : 1417-1424
64. Bennett J.M., Catovsky D., Daniel M.T. Et Al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 1982, 51 : 189-199
65. Cazzola M., Barosi G., Gobbi P.G. Et Al. Natural history of idiopathic refractory sideroblastic anemia. Blood, 1988, 71 : 305-312.
66. Rosati S., Anastasi J., Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Sem. Hematol., 1996, 33 : 111-126
67. Lambertenghi-Deliliers G., Annaloro C., Oriani A, Et Al. Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk. Lymphoma, 1992, 8 : 51-55
68. Mangi M.H., Mufti G.J. Primary myelodysplastic syndromes : diagnostic and prognostic significance of immuno-histochemical assessment of bone marrow biopsies. Blood, 1992, 79 : 198-205.
69. Galton D.A.G. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk. Lymph., 1992, 7 : 343-350.
70. Lai J.L., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Wattel E., Fenaux P. Myelodypslastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by ecific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia, 1995, 15
71. Fonatsch C., Gudat H., Lengfelder E Et Al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).Leukemia, 1994, 8 : 1318-26
72. Ohyashiki J.H., Ohyashiki K., Shimamoto T. Et Al. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia : possible association with GATA-1, GATA-2 and stem cell leukemia gene expression. Blood, 1995, 85 : 3713-18
73. Castleberry R.P., Emanuel P.D., Zuckerman K.S., Cohn S., Strauss L., Byrd R.L., Homans A., Chaffee S., Nitschke R., Gualtieri R.J. A pilot study of isoretinoin inthe treatment of juvenile chronic myelogenous leukemia. N. Engl. J. Med., 1994, 331 : 1680-1684
74. Suciu S., Kuse R., Weh H.J. Et Al. Results of chromosome studies and their relation to porphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet.Cytogenet., 1990, 44 : 15-26
75. Wattel E. Lai J.L., Hebbar M. Et Al. Deletion of the long arm of chromosome 20 in de novo myelodysplastic syndromes is associated with distinct hematological and prognsotic features. Leuk.Res., 1993, 17 : 921-926
76. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes : a scoring system with prognostic significance. Br. J. HaematoL, 1985, 59 : 425-433
77. Sanz G,F., Sanz M.A., Vallespi T. Et Al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes : a multivariate analysis of prognostic factors in 370 patients. Blood, 1989, 74 : 395-408
78. Aul C., Gattermann N., Heylla Et Al. Primary myelodysplastic syndromes : analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 1992, 6 : 52-59
79. Morel P., Declercq C., Hebbar M., Bauters F., Fenaux P. Prognostic factors in myelodysplastic syndromes : critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br. J. Haematol., 1996, 94
80. Lepelley P., Soenen V., Preudhomme C., Lai JI., Cosson A., Fenaux P. Expression of the multidrug resistance P glycoprotein and its relation-ship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 1994, 8 : 998-1005
81. Fenaux P., Morel P., Rose C., Lai J.L., Jouet J.P., Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol., 1991, 77 : 497-501
82. Hellstrom-Lingberg E., Robert K.H., Gahrton G., Lindberg G. A predictive model for the clinical response to low-dose Ara-C : a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br. J. Haematol., 1992, 81 : 503-11
83. Anderson J.E., Appelbaum F.R., Fisher I.D. Et Al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 1993 : 82 : 677-81
84. Sutton L., Leblond V., Le Maignan C. Et Al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone marrow Transplant., 1991, 7, suppl. 2: 39
85. De Witte T., Zwaan F., Hermans J. Et Al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome : a survey by the leukaemia Working Party of the European Bone Marrow Transplantation Grup (EBMTG). Br. J. Haematol., 1990, 74 : 151
86. Anderson J.E., Appelbaum F.R., Shoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology : a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol., 1996, 14 : 220-226
87. Anderson J.E., Anasetti C., Appelbaum F.R., Schoch G., Gooley T.A., Hansen J.A., Buckner C.D., Sanders J.E., Sullivan K.M., Storb R. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br. J. Haematol., 1996, 93 : 59-67
88. Hoyle C., De Bastos C., Wheatley K. Et Al. AML associated with previous chemotherapy MDS or myeloproliferative disorders : results from the MRC's 9th AML trial. Brit. J. Haematol., 1989, 72 : 45-53
89. Gajewski J., Ho W., Nimer S. Et Al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J. Clin. Oncol., 1989, 7 : 1637-45
90. De Witte T., Muus P., De Pauw B., Haanen C Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 1990, 66 : 831-7
91. Fenaux P., Preudhomme C., Hebbar M. The role of intensive chemotherapy in myelodysplastic syndromes. Leuk. Lymph., 1992, 8 : 43-9
92. Michels S.D., Mc Kenna R.W., Arthur D.C., Brunning R.D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome : a clinical and morphologic study of 65 cases. Blood, 1985, 65 : 1364-72
93. Estey E., Thall P., Andreeff M.Et Al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes : comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol., 1994, 12 : 671-8
94. Aul C., Runde V., Gattermann N. Et Al. Treatment of advanced primary myelodysplastic syndromes with AML-rype chemotherapy : results in 76 patients. Leuk. Res., 1994, 18, suppl. : 22 (abstr)
95. De Witte T., Suciu S., Peetermans M. Et Al. A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A study by the Leukemia Cooperative Group of European Organisation for Treatment and Research in Cancer (EORTC-LCG), 1994
96. Bernstein S., Brunetto V., Davey F. Et Al. Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 1993, 82, suppl. : 1960 (abstr.)
97. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. P53 mutations are associated to resistance to chemotherapy and short survival in hematologic malignancies. Blood (in press)
98. Delforge M., Demuynck H., Vandenberghe P., Verhoef G., Zachee P., Van Duppen V., Marijnen P., Van Den Berghe H., Boogaerts M.A. Polyclonal primitive hematopoietic progenitors can be tected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood, 1995, 86 : 3660-3667
99. Demuynck H., Delforge M., Verhoef G.E.G., Zachee P., Vandenberghe P., Van Den Berghe H., Boogaerts M.A. Ffeasibility of peripharal blood progenictor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br. J. Haematol., 1996, 92 : 351-359
100. Laporte J.P., Isnard F., Lesage S. Fenaux P. Et Al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transplantation (AML-MDS) : a pilot study. Leukemia (in press)
101. Cheson B.D., Jasperse D.M., Simon R., Friedman M.A. A critical appraisal of low-dose Ara C in patients with acute non tymphocytic leukemia and myelodysplastic syndromes. J. Clin oncol., 1986, 4 : 1857-64
102. Miller K.B., Kyungmann K., Morrison F.S. Et Al. The evaluation of low-dose cytarabine in the treatment of myelodyspiastic syndromes : a phase III intergroup study. Ann. Hematol., 1992, 65 : 162-8
103. Silverman L.R., Holland J.F., Weinberg R.S. Et Al. Effects of treatment with 5-azacytidine of the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia, 1993, 7, suppl 1 : 21-9
104. Andreeff M., Stone R., Michaeli J. Et Al.Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia : a phase II clinical trial with a differentiation-inducing agent. Blood, 1992, 80 : 2604-9
105. Ganser A., Hoelzer D. Treatment of myelodyspiastic syndromes with hematopoietic growth factors. Hemat. Oncol. Clin. N. Am., 1992, 6 : 633-648
106. Schuster M.W., Thompson J.A., Larson R., Coiffier B. Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) vs observation in patients with myelodysplastic syndrome. J. Cancer Res. Clin. Oncol., 1990, 116 : 1079-1086
107. Rose C., Wattel E., Bastion Y., Berger E., Bauters F., Coiffier B., Fenaux P. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 29 cases. Leukemia, 1994, 8 : 1458-1462
108. Hellstrom-Lindberg E For The Scandinavian MDS Group. A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anemia in patients with myelodysplastic syndromes. Leukemia and Lymphoma 1993, 11 : 221-228
109. Cambier N., Wattel E., Menot M.L., Guerci A., Chomienne C., Fenaux P. All transretinoic acid in adult chronic myelomonocytic leukemia : results of a pilot study. Leukemia (in press)
110. Wattel E., Guerci A., Hecuet B., Economopoulos T., Copplestone A., Mahe B., Couteaux M.E., Resegotti L., Voglova V., Foussard C., Pegourie B., Michaux J-L., Deconinck E., Stoppa A.M., Mufti G., Oscier D., Fenaux P. A randomized trial of hydroxyurea versus VP 16 in adult chronic myelomonocytic leukemia. Blood (in press)